Compare Baidu Inc (BIDU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baidu Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Baidu Inc trades at $112.28 (market cap $36.80B), while Vertex Pharmaceuticals Incorporated trades at $473.92 (market cap $120.89B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× Baidu Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| BIDU | VRTX | |
|---|---|---|
Market Cap | $36.80B | $120.89B |
Sector | Media | Health |
52-Week High | $162.52 | $529.59 |
52-Week Low | $85.86 | $366.54 |
Enterprise Value | $33.45B | $115.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $113.39, down 3.52% amid bearish technical signals and mixed fundamentals. The stock faces pressure from declining revenue and net income margins, though it maintains strong analyst support with a $161 consensus price target. Recent news highlights AI optimism from Kunlunxin's potential $50 billion Hong Kong IPO, while cash flow trends show significant investing outflows. Technical indicators show bearish moving averages with neutral oscillators, trading near key support at $112.
Baidu presents a high-risk opportunity with Wall Street maintaining bullish ratings despite recent earnings volatility. The AI pivot and potential chip unit IPO offer growth catalysts, but declining profitability and negative cash flows pose substantial risks. Investors should weigh strong balance sheet strength against execution challenges in China's competitive tech landscape.
Vertex Pharmaceuticals (VRTX) trades at $480.25, down 1.06% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 35.51% net income margin and consistent earnings beats, while the recent $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio with up to $5 billion in peak sales potential.
The outlook remains positive given Wall Street's consensus buy rating and $538 price target, though integration risks from the Crinetics deal and past earnings volatility warrant caution. Revenue growth and margin strength position VRTX for upside, but investors should weigh acquisition execution against competitive and regulatory pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
